Top reasons for recalls include software, quality and parts issues.
A review of new, successful treatment options for the novel coronavirus.
No longer just “the big company advantage,” CM&S is an accepted and viable device industry path to market for large and small medical device makers alike.
Lucira Health’s single-use molecular test kit will be available for prescription home use in people age 14 and older.
Moving too quickly in the product development process can lead to mistakes.
An upcoming webinar will discuss the new methods and protocols that have emerged as a result of conducting trials and HF studies during the pandemic.
Part three of this series discusses the key defenses available to each element of a lawsuit against providers and labs.
To avoid delays in timelines, companies should develop IFU cleaning instructions with the worst-case clinical use and contamination method in mind.
The serology test is the first of its kind to detect neutralizing antibodies from a recent or prior SARS-CoV-2 infection.
The pandemic is helping realize the potential of ISO IDMP data standards in relation to adverse event reporting, electronic prescribing and medicines control in the supply chain.